Clinical validity, on the other hand, addresses how well the test results correlate with the intended clinical outcome, such as predicting disease risk or guiding treatment response. Unlike therapeutic drugs which are evaluated primarily for safety and efficacy, diagnostics are assessed on a dual-axis of analytical validity and clinical validity.
Post Market Surveillance Diagnostics Requirements for Ongoing Compliance and Safety
The World Health Organization (WHO) leads the Global Initiative for In Vitro Diagnostics (GIVD), which aims to establish uniform norms and guidance for manufacturers and regulators. However, these requirements ultimately serve to build trust in the diagnostic ecosystem.
For manufacturers, the cost of compliance is a significant strategic consideration. Furthermore, the concept of lifecycle management is central to current regulation.
Implementing Post Market Surveillance for Diagnostic Compliance
This alignment is particularly crucial for emerging markets looking to adopt best practices without reinventing regulatory wheels. This continuous feedback loop ensures that diagnostics evolve alongside scientific understanding, maintaining their relevance and safety over time.
More About In vitro diagnostic regulation
Looking at In vitro diagnostic regulation from another angle can help expand the discussion and give readers a second clear paragraph under the same section.
More perspective on In vitro diagnostic regulation can make the topic easier to follow by connecting earlier points with a few simple takeaways.
